Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

NASDAQ:RPHM

Overview | Financials
Company Name Reneo Pharmaceuticals, Inc.
Symbol RPHM
Currency USD
Price 18.2
Market Cap 60,840,416
Dividend Yield 0%
52-week-range 1.68 - 82.9
Industry Biotechnology
Sector Healthcare
CEO Mr. Gregory J. Flesher
Website https://reneopharma.com

An error occurred while fetching data.

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical

Related Stocks

Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

ALGS

39.34 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

1.18 USD

Daxor Corporation logo

Daxor Corporation

DXR

7.95 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.454 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

3.92 USD

Financials

Numbers are in millions USD

Numbers are in millions USD